Innovation Pharmaceuticals Inc. (IPIX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 7.51 Million USD | -27.57% |
| 2022 | 10.37 Million USD | -27.41% |
| 2021 | 14.29 Million USD | 54.62% |
| 2020 | 9.24 Million USD | 128.57% |
| 2019 | 4.04 Million USD | -38.14% |
| 2018 | 6.54 Million USD | -28.22% |
| 2017 | 9.11 Million USD | -20.38% |
| 2016 | 11.44 Million USD | -20.07% |
| 2015 | 14.31 Million USD | 31.95% |
| 2014 | 10.85 Million USD | 265.32% |
| 2013 | 2.97 Million USD | 10498.38% |
| 2012 | 28.02 Thousand USD | -91.05% |
| 2011 | 313.09 Thousand USD | 207.5% |
| 2010 | 101.82 Thousand USD | -34.41% |
| 2009 | 155.23 Thousand USD | -65.49% |
| 2008 | 449.77 Thousand USD | 1841.04% |
| 2007 | 23.17 Thousand USD | 11.63% |
| 2006 | 20.75 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 6.66 Million USD | -11.31% |
| 2023 Q4 | 7.51 Million USD | -5.96% |
| 2023 Q2 | 8.69 Million USD | -6.93% |
| 2023 Q1 | 9.33 Million USD | -10.03% |
| 2023 FY | 7.51 Million USD | -27.57% |
| 2023 Q3 | 7.99 Million USD | -8.03% |
| 2022 Q4 | 10.37 Million USD | -10.97% |
| 2022 Q1 | 14.73 Million USD | 3.01% |
| 2022 FY | 10.37 Million USD | -27.41% |
| 2022 Q2 | 13.06 Million USD | -11.28% |
| 2022 Q3 | 11.65 Million USD | -10.79% |
| 2021 Q4 | 14.29 Million USD | -15.51% |
| 2021 FY | 14.29 Million USD | 54.62% |
| 2021 Q2 | 12.4 Million USD | 6.13% |
| 2021 Q1 | 11.69 Million USD | 26.42% |
| 2021 Q3 | 16.92 Million USD | 36.4% |
| 2020 Q2 | 3.49 Million USD | -19.0% |
| 2020 Q4 | 9.24 Million USD | 130.68% |
| 2020 Q1 | 4.31 Million USD | 6.65% |
| 2020 Q3 | 4 Million USD | 14.71% |
| 2020 FY | 9.24 Million USD | 128.57% |
| 2019 Q4 | 4.04 Million USD | 0.95% |
| 2019 FY | 4.04 Million USD | -38.14% |
| 2019 Q3 | 4 Million USD | -9.05% |
| 2019 Q1 | 4.3 Million USD | -34.18% |
| 2019 Q2 | 4.4 Million USD | 2.37% |
| 2018 Q3 | 5.75 Million USD | -25.67% |
| 2018 Q2 | 7.73 Million USD | 1.03% |
| 2018 Q1 | 7.65 Million USD | -15.95% |
| 2018 FY | 6.54 Million USD | -28.22% |
| 2018 Q4 | 6.54 Million USD | 13.72% |
| 2017 Q1 | 10.9 Million USD | -4.73% |
| 2017 FY | 9.11 Million USD | -20.38% |
| 2017 Q4 | 9.11 Million USD | -13.32% |
| 2017 Q3 | 10.51 Million USD | 19.56% |
| 2017 Q2 | 8.79 Million USD | -19.37% |
| 2016 Q2 | 11.89 Million USD | -11.96% |
| 2016 Q4 | 11.44 Million USD | 1.33% |
| 2016 Q3 | 11.29 Million USD | -5.05% |
| 2016 FY | 11.44 Million USD | -20.07% |
| 2016 Q1 | 13.51 Million USD | -5.64% |
| 2015 Q2 | 14.85 Million USD | 18.66% |
| 2015 FY | 14.31 Million USD | 31.95% |
| 2015 Q4 | 14.31 Million USD | -16.13% |
| 2015 Q1 | 12.51 Million USD | 15.36% |
| 2015 Q3 | 17.07 Million USD | 14.92% |
| 2014 Q3 | 10.3 Million USD | -2.46% |
| 2014 Q2 | 10.56 Million USD | 12.95% |
| 2014 Q1 | 9.35 Million USD | 214.79% |
| 2014 Q4 | 10.85 Million USD | 5.34% |
| 2014 FY | 10.85 Million USD | 265.32% |
| 2013 Q2 | 534.91 Thousand USD | 279.81% |
| 2013 FY | 2.97 Million USD | 10498.38% |
| 2013 Q3 | 1.34 Million USD | 150.64% |
| 2013 Q4 | 2.97 Million USD | 121.57% |
| 2013 Q1 | 140.83 Thousand USD | 402.48% |
| 2012 Q2 | 882.73 Thousand USD | 2235.65% |
| 2012 FY | 28.02 Thousand USD | -91.05% |
| 2012 Q4 | 28.02 Thousand USD | -72.04% |
| 2012 Q3 | 100.25 Thousand USD | -88.64% |
| 2012 Q1 | 37.79 Thousand USD | -87.93% |
| 2011 Q2 | 414.72 Thousand USD | 267.72% |
| 2011 FY | 313.09 Thousand USD | 207.5% |
| 2011 Q1 | 112.78 Thousand USD | 10.77% |
| 2011 Q4 | 313.09 Thousand USD | 110.16% |
| 2011 Q3 | 148.97 Thousand USD | -64.08% |
| 2010 Q3 | 80.27 Thousand USD | 34.53% |
| 2010 FY | 101.82 Thousand USD | -34.41% |
| 2010 Q4 | 101.82 Thousand USD | 26.84% |
| 2010 Q2 | 59.67 Thousand USD | -56.23% |
| 2010 Q1 | 136.32 Thousand USD | -12.18% |
| 2009 Q1 | 431.75 Thousand USD | -4.01% |
| 2009 Q3 | 168.39 Thousand USD | -34.44% |
| 2009 Q2 | 256.85 Thousand USD | -40.51% |
| 2009 FY | 155.23 Thousand USD | -65.49% |
| 2009 Q4 | 155.23 Thousand USD | -7.81% |
| 2008 Q4 | 449.77 Thousand USD | 2807.6% |
| 2008 Q3 | 15.46 Thousand USD | 3198.29% |
| 2008 Q2 | 469.00 USD | -96.28% |
| 2008 Q1 | 12.6 Thousand USD | -45.62% |
| 2008 FY | 449.77 Thousand USD | 1841.04% |
| 2007 Q4 | 23.17 Thousand USD | -12.15% |
| 2007 FY | 23.17 Thousand USD | 11.63% |
| 2007 Q2 | 26.47 Thousand USD | -9.93% |
| 2007 Q3 | 26.37 Thousand USD | -0.38% |
| 2007 Q1 | 29.39 Thousand USD | 0.0% |
| 2006 FY | 20.75 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -325311.255% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -283.875% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 28.776% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -1261.479% |
| Rebus Holdings, Inc. | 5000.00 USD | -150240.0% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 94.227% |
| Qrons Inc. | 420.00 USD | -1789661.905% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -875.418% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 73.1% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -1464.227% |
| Skye Bioscience, Inc. | 11.94 Million USD | 37.046% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 80.65% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -4.117% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -9744.933% |
| SQZ Biotechnologies Company | 107.18 Million USD | 92.987% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -424.918% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -10287.618% |
| Mesoblast Limited | 667.9 Million USD | 98.875% |
| Marizyme, Inc. | 22.01 Million USD | 65.855% |
| Genus plc | 1.02 Billion USD | 99.269% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -453.391% |
| Pharming Group N.V. | 462.85 Million USD | 98.376% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -126.893% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -1406.295% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -1098.884% |
| ContraFect Corporation | 20.67 Million USD | 63.649% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -1825.629% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -1866.89% |
| IMV Inc. | 31.33 Million USD | 76.01% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -81.306% |
| MultiCell Technologies, Inc. | 126.22 USD | -5955374.568% |
| ONE Bio Corp. | 70.08 Million USD | 89.275% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -699.946% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 94.151% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -1641.199% |
| Q BioMed Inc. | 3.51 Million USD | -113.823% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 78.632% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -2777.023% |
| Biomind Labs Inc. | 73.81 Thousand USD | -10083.015% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 98.316% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -418.828% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 74.956% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -173.71% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -993.404% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -188.76% |
| GB Sciences, Inc. | 103.44 Thousand USD | -7166.874% |
| Alpha Cognition Inc. | 2.45 Million USD | -206.545% |
| HST Global, Inc. | 1526.00 USD | -492495.02% |
| CSL Limited | 38.02 Billion USD | 99.98% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -660.855% |
| Halberd Corporation | 10.13 Thousand USD | -74098.006% |
| Enzolytics Inc. | 361.7 Million USD | 97.922% |
| Agentix Corp. | 261.39 Thousand USD | -2775.757% |
| Resverlogix Corp. | 8.11 Million USD | 7.369% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -300.292% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.835% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 84.242% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -1075.163% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -32896.796% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 16.003% |
| AVAX Technologies, Inc. | 7.37 Million USD | -1.896% |
| Zenith Capital Corp. | 7410.00 USD | -101343.995% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.778% |
| Ember Therapeutics, Inc. | 184.00 USD | -4085226.087% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -2235.879% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -2776.066% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -710.056% |
| Kadimastem Ltd | 2.3 Million USD | -226.247% |
| Helix BioMedix, Inc. | 3.02 Million USD | -148.489% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 85.737% |
| BioStem Technologies, Inc. | 14.56 Million USD | 48.373% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -13066.007% |
| LadRx Corporation | 2.3 Million USD | -225.71% |
| Cell Source, Inc. | 195.17 Thousand USD | -3751.494% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -2025.746% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -2025.746% |
| NovAccess Global Inc. | 62.24 Thousand USD | -11975.89% |
| Affymax, Inc. | 7.44 Million USD | -0.994% |
| Itoco Inc. | 1.4 Million USD | -436.901% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -7758.285% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -6991.509% |
| Mobile Lads Corp. | 52.00 USD | -14455669.231% |
| CytoDyn Inc. | 11.13 Million USD | 32.498% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -5157.673% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -41941.387% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -1850.082% |
| SYBLEU INC | 330.46 Thousand USD | -2174.653% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -1736.003% |
| International Stem Cell Corporation | 5.39 Million USD | -39.462% |
| Bioxytran, Inc. | 137.63 Thousand USD | -5361.428% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 49.893% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 54.66% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -9415.19% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -769.342% |
| Neutra Corp. | 2851.00 USD | -263561.873% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 76.804% |
| PureTech Health plc | 693.97 Million USD | 98.917% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 6.865% |
| IXICO plc | 15.84 Million USD | 52.556% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 9.237% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 92.725% |
| CSL Limited | 38.02 Billion USD | 99.98% |
| Cellectis S.A. | 333.99 Million USD | 97.749% |